Categories: Health

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025

Aggregated presentation by day and by market

Statement of transactions in own shares from 1st September to 5th September 2025
             
Name of the issue Identity code of the issuer
(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market         (MIC Code)
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    632 116,87753 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   1 200 116,94167 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150    200 116,90 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 01/09/2025 FR0010259150   2 606 117,18388 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    300 116,20 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    500 116,20 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150    200 116,286 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 02/09/2025 FR0010259150   3 600 116,41622 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,70 AQEU  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    600 116,68333 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150    300 116,50967 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 03/09/2025 FR0010259150   3 400 116,95335 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   1 200 120,00 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 04/09/2025 FR0010259150   3 400 119,88147 XPAR  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 € AQEU  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    600 120,05 CCXE  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150    300 120,00 TQEX  
  IPSEN 549300M6SGDPB4Z94P11 05/09/2025 FR0010259150   3 400 119,80815 XPAR  
            23 038 118,01642    
                 
GlobeNews Wire

Share
Published by
GlobeNews Wire
Tags: 2025Adventureartbuy-backFR0010259150ipsenmar”newsParis:IPNPressReleaseprogrammeRegulated_Infoweek
8 months ago

Recent Posts

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical…

6 hours ago

Avactapresents new comparisons of pre|CISIONpayload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

May 06, 2026 02:00 ET  | Source: Avacta Group PLC LONDON and PHILADELPHIA, May 06,…

6 hours ago

Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to…

6 hours ago

Forever Starts Here: Why the Philippines is Asia’s Next Dream Destination for Weddings and Romance Travel

MANILA, Philippines, May 6, 2026 /PRNewswire/ -- The Philippines is emerging as one of Asia's…

6 hours ago

European Company P3 Establishes AI Factory in India to Drive Rapid Global Scale-Up

Offices in Chennai and Pune to anchor global AI innovation and delivery.STUTTGART, Germany and CHENNAI,…

9 hours ago

GGGI Onboards ISGF to Amplify ALCBT (Asia Low Carbon Buildings Transition) Project Outreach, Accelerating India’s Transition to Low-Carbon Buildings

NEW DELHI, May 6, 2026 /PRNewswire/ -- The Asia Low Carbon Buildings Transition (ALCBT) Project…

9 hours ago